Interferon-β Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Glioblastoma is the most common malignant brain tumor in adults and characterized by a poor prognosis. Glioma cells expressing O6-methylguanine DNA methyltransferase (MGMT) exhibit a higher level of resistance toward alkylating agents, including the standard of care chemotherapeutic agent temozolomide. Here, we demonstrate that long-term glioma cell lines (LTL) as well as glioma-initiating cell lines (GIC) express receptors for the immune modulatory cytokine IFN-β and respond to IFN-β with induction of STAT-3 phosphorylation. Exposure to IFN-β induces a minor loss of viability, but strongly interferes with sphere formation in GIC cultures. Furthermore, IFN-β sensitizes LTL and GIC to temozolomide and irradiation. RNA interference confirmed that both IFN-β receptors, R1 and R2, are required for IFN-β–mediated sensitization, but that sensitization is independent of MGMT or TP53. Most GIC lines are highly temozolomide-resistant, mediated by MGMT expression, but nevertheless susceptible to IFN-β sensitization. Gene expression profiling following IFN-β treatment revealed strong upregulation of IFN-β–associated genes, including a proapoptotic gene cluster, but did not alter stemness-associated expression signatures. Caspase activity and inhibition studies revealed the proapoptotic genes to mediate glioma cell sensitization to exogenous death ligands by IFN-β, but not to temozolomide or irradiation, indicating distinct pathways of death sensitization mediated by IFN-β. Thus, IFN-β is a potential adjunct to glioblastoma treatment that may target the GIC population. IFN-β operates independently of MGMT-mediated resistance, classical apoptosis-regulatory networks, and stemness-associated gene clusters. Mol Cancer Ther; 13(4); 948–61. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STRING v9.1: protein-protein interaction networks, with increased coverage and integration
Franceschini, A., Szklarczyk, D., Frankild, S., Kuhn, M., Simonovic, M., Roth, A., Lin, J., Minguez, P., Bork, P., von Mering, C., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1094 · Cited by 4,398
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6968 · Cited by 1,063
Ishii, N., Maier, D., Merlo, A., Tada, M., Sawamura, Y., Diserens, A., & Van Meir, E. G. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00536.x · Cited by 569 · cited 1×
“These reports, however, were based on findings in T98G and U251MG, both being TP53-mutant cell lines (22, 23).”
BackgroundInterferon‐Induced Mx Proteins: Dynamin‐Like GTPases with Antiviral Activity
Haller, O., & Kochs, G. (2002) · Traffic · doi:10.1034/j.1600-0854.2002.31003.x · Cited by 460 · cited 1×
“Downstream signaling pathways involve the Janus kinase/signal Transducers and Activators of Transcription (JAK/STAT) pathway (14) and lead to accumulation of myxovirus resistance 1 (MxA) protein, a GTPase interfering with the cytoskeletal structure (15, 16).”
BackgroundCP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death
Wischhusen, J., Naumann, U., Ohgaki, H., Rastinejad, F., & Weller, M. (2003) · Oncogene · doi:10.1038/sj.onc.1207198 · Cited by 158 · cited 3×
“These reports, however, were based on findings in T98G and U251MG, both being TP53-mutant cell lines (22, 23).”
BackgroundSelf-citation
Cited by
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)
Yalamarty, S. S. K., Filipczak, N., Li, X., Subhan, M. A., Parveen, F., Ataide, J. A., Rajmalani, B. A., & Torchilin, V. P. (2023) · Cancers · doi:10.3390/cancers15072116 · Cited by 293
Hombach-Klonisch, S., Mehrpour, M., Shojaei, S., Harlos, C., Pitz, M., Hamai, A., Siemianowicz, K., Likus, W., Wiechec, E., Toyota, B. D., et al. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.017 · Cited by 292
Biological activity of tumor-treating fields in preclinical glioma models
Silginer, M., Weller, M., Stupp, R., & Roth, P. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.171 · Cited by 111
Self-citationStojcheva, N., Schechtmann, G., Sass, S., Roth, P., Florea, A.-M., Stefanski, A., Stühler, K., Wolter, M., Müller, N. S., Theis, F. J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7346 · Cited by 50
Self-citation
Metadata
- Authors
- Happold, C., Roth, P., Silginer, M., Florea, A.-M., Lamszus, K., Frei, K., Deenen, R., Reifenberger, G., & Weller, M.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2014-04-01
- Volume
- 13
- Issue
- 4
- Pages
- 948-961
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2158665609
- Cited by
- 48
- References
- 5
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interferon-β Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells. https://app.cochat.ai/papers/10.1158/1535-7163.mct-13-0772
- The paper
- Happold, C., Roth, P., Silginer, M., Florea, A.-M., Lamszus, K., Frei, K., Deenen, R., Reifenberger, G., & Weller, M. (2014). Interferon-β Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-13-0772
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.